Stockscreener 앱 받기
6.635
0.23%
0.015
전일 마감가:
$6.62
열려 있는:
$6.61
하루 거래량:
50,865
Relative Volume:
0.74
시가총액:
$190.19M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-10.82%
1개월 성능:
+30.10%
6개월 성능:
+134.45%
1년 성능:
+0.00%
1일 변동 폭
$6.47
$7.15
1주일 범위
$6.47
$7.44
52주 변동 폭
$2.33
$8.51
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
명칭
Insight Molecular Diagnostics Inc
전화
949-409-7600
주소
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
IMDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
6.635 | 189.76M | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
618.72 | 234.69B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
235.99 | 169.45B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
715.37 | 56.86B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
237.68 | 41.09B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
139.64 | 41.06B | 6.95B | 1.30B | 1.15B | 4.5696 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-28 | 개시 | Lake Street | Buy |
| 2022-05-24 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | 개시 | Stephens | Overweight |
| 2022-01-06 | 재개 | Piper Sandler | Overweight |
| 2021-03-17 | 재개 | Needham | Buy |
| 2021-01-07 | 업그레이드 | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | 개시 | BTIG Research | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | 재확인 | The Benchmark Company | Speculative Buy |
| 2020-07-01 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | 개시 | Needham | Buy |
| 2019-02-13 | 개시 | Piper Jaffray | Overweight |
| 2019-01-29 | 업그레이드 | Janney | Neutral → Buy |
| 2018-12-19 | 재개 | Lake Street | Buy |
모두보기
Insight Molecular Diagnostics Inc 주식(IMDX)의 최신 뉴스
IMDX Supports AST and ASHI STAR Working Group's Call for Decentralized Transplant Monitoring - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Inogen (INGN), Exelixis (EXEL) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring - GlobeNewswire
iMDx Announces 'JPM Week” and 'BTIG Snowbird” Conference Participation - The Manila Times
iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation - GlobeNewswire
iMDx to Welcome Industry Veteran as Vice President of - GlobeNewswire
iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch - Sahm
Is Insight Molecular Diagnostics Inc. (7OC0) stock considered safe haven2026 world cup usa national team quarterfinals midfield engines low block defense group prediction preview - Улправда
Needham reiterates Buy rating on Insight Molecular stock, cites progress on GraftAssureDx - Investing.com Nigeria
Insight Molecular Diagnostics Inc. Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion - marketscreener.com
Insight Molecular Diagnostics (IMDX) Nears Key FDA Submission Mi - GuruFocus
IMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion - MarketScreener
iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion - Sahm
iMDx Stock Rebounds After-Hours As Study Shows Transplant Test Works As Well As Market Standard - MSN
Prostate Cancer Diagnostics Market Size Report, 2026 – 2035 - Global Market Insights Inc.
Insight Molecular Diagnostics Inc.Common Stock (NQ: IMDX - FinancialContent
KIFFIK Biomedical Closes Oversubscribed Series A to Advance Real-Time Molecular Diagnostics Platform - The Newark Advocate
Insiders Rewarded With US$5.2m Addition To Investment As Insight Molecular Diagnostics Stock Hits US$183m - Yahoo Finance
Molecular Cytogenetics Market Analysis Reveals Growth - openPR.com
Insight Molecular (IMDX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Insight Molecular Diagnostics (FRA:7OC0) EV-to-OCF : -5.98 (As of Dec. 24, 2025) - GuruFocus
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), MDxHealth (MDXH) and RxSight (RXST) - The Globe and Mail
Hedge funds investors control 50% of Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) and were rewarded last week after stock increased 11% - simplywall.st
Animal Health Market Size, Share & Industry Trends Analysis Report [2032] - Fortune Business Insights
Why Insight Molecular Diagnostics Inc. (7OC0) stock attracts HNW investorsQuarterly Risk Review & Verified Short-Term Trading Plans - DonanımHaber
Biosensors Market Size, Share & Analysis | Growth Report [2032] - Fortune Business Insights
United States Molecular Diagnostics Market Trends & Summary - vocal.media
Page not foundFactor Thisâ„¢ - FinancialContent
Is Insight Molecular Diagnostics Inc. (7OC0) stock suitable for passive index fundsJuly 2025 Update & Short-Term Trading Opportunity Alerts - Newser
Is Insight Molecular Diagnostics Inc. (7OC0) stock a safe buy pre earningsMarket Sentiment Review & Safe Capital Preservation Plans - Newser
Will Insight Molecular Diagnostics Inc. (7OC0) stock sustain dividend payoutsOptions Play & Real-Time Volume Trigger Notifications - Newser
Why global investors buy Insight Molecular Diagnostics Inc. (7OC0) stock2025 Technical Patterns & Stepwise Entry/Exit Trade Alerts - Newser
Why Insight Molecular Diagnostics Inc. (7OC0) stock stays resilientMarket Movers & Real-Time Buy Zone Alerts - Newser
How Insight Molecular Diagnostics Inc. (7OC0) stock compares with market leaders2025 Big Picture & High Conviction Buy Zone Picks - Newser
Pullback Watch: Can Insight Molecular Diagnostics Inc 7OC0 stock beat analyst consensusEarnings Recap Report & Verified Momentum Stock Ideas - moha.gov.vn
We're Keeping An Eye On Insight Molecular Diagnostics' (NASDAQ:IMDX) Cash Burn Rate - Yahoo Finance
Specialty Enzymes Market will reach $12.71 Billion by 2033Strategic Revenue Insights - industrytoday.co.uk
Diagnostic Specialty Enzymes Market will reach US$2.49 Billion by 2033Strategic Revenue Insights - industrytoday.co.uk
Tissue Diagnostic Market will reach US$25.07 Billion by 2033Strategic Revenue Insights - industrytoday.co.uk
Transplant Monitoring Kits Market Size, Share | CAGR Of 4.6% - Market.us
Insight Molecular Diagnostics Inc (IMDX) 재무 분석
Insight Molecular Diagnostics Inc (IMDX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Insight Molecular Diagnostics Inc 주식 (IMDX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| James Andrea S. | Chief Financial Officer |
Feb 07 '25 |
Buy |
2.05 |
97,561 |
200,000 |
151,231 |
| SMITH PATRICK W | 10% Owner |
Feb 07 '25 |
Buy |
2.05 |
1,077,600 |
2,209,080 |
2,872,671 |
| BROADWOOD PARTNERS, L.P. | 10% Owner |
Feb 06 '25 |
Buy |
2.05 |
5,165,695 |
10,589,675 |
11,410,100 |
| SMITH PATRICK W | 10% Owner |
Jan 31 '25 |
Buy |
2.01 |
890 |
1,789 |
1,795,046 |
| SMITH PATRICK W | 10% Owner |
Feb 04 '25 |
Buy |
2.02 |
25 |
50 |
1,795,071 |
| SMITH PATRICK W | 10% Owner |
Jan 29 '25 |
Buy |
2.01 |
3,880 |
7,799 |
1,793,838 |
| SMITH PATRICK W | 10% Owner |
Jan 30 '25 |
Buy |
2.01 |
318 |
639 |
1,794,156 |
2.51%
0.74%
자본화:
|
볼륨(24시간):